Drugs / CKD-330
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04478097 | Jul → Nov 2020 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04019743 | Jul → Aug 2019 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03849287 | Feb → Mar 2019 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03659149 | Aug → Oct 2018 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03017950 | Dec 2016 → Mar 2017 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03583905 | Apr 2018 → Jul 2019 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT02586311 | Jan → Aug 2016 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04478097 ↗ |
| Route | Oral | “CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.” NCT02586311 ↗ |